Grand Pharmaceutical Group Ltd
HKEX:512
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.28
5.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Grand Pharmaceutical Group Ltd
Accounts Receivables
Grand Pharmaceutical Group Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Accounts Receivables
HK$4.5B
|
CAGR 3-Years
41%
|
CAGR 5-Years
27%
|
CAGR 10-Years
21%
|
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Accounts Receivables
HK$2.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Accounts Receivables
¥5.4B
|
CAGR 3-Years
23%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Accounts Receivables
¥7.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
16%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Accounts Receivables
HK$77.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Accounts Receivables
$159.8m
|
CAGR 3-Years
39%
|
CAGR 5-Years
30%
|
CAGR 10-Years
20%
|
|
Grand Pharmaceutical Group Ltd
Glance View
Grand Pharmaceutical Group Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The firm is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
See Also
What is Grand Pharmaceutical Group Ltd's Accounts Receivables?
Accounts Receivables
4.5B
HKD
Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's Accounts Receivables amounts to 4.5B HKD.
What is Grand Pharmaceutical Group Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
21%
Over the last year, the Accounts Receivables growth was 117%. The average annual Accounts Receivables growth rates for Grand Pharmaceutical Group Ltd have been 41% over the past three years , 27% over the past five years , and 21% over the past ten years .
You don't have any saved screeners yet
